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Abstract
In spite of both having features of germinal center B-cells, Burkitt lymphomas and follicular 
lymphomas are biologically and clinically quite diverse. We here performed whole genome 
bisulfite, genome and transcriptome sequencing from 13 IG-MYC-translocation positive Burkitt 
lymphoma, 9 BCL2-translocation positive follicular lymphoma and four normal germinal center 
B-cell samples. Comparison of Burkitt and follicular lymphoma samples revealed differential 
methylation of intragenic regions that strongly correlated with expression of associated genes, e.g. 
genes active in germinal center dark zone and light zone B-cells. Integrative pathway analyses of 
regions differentially methylated between Burkitt and follicular lymphoma implicated DNA 
methylation to cooperate with somatic mutation of sphingosine-phosphate signaling, as well as the 
TCF3/ID3 and SWI/SNF complexes in a large fraction of Burkitt lymphomas. Taken together, our 
results demonstrate a tight connection between somatic mutation, DNA methylation and 
transcriptional control in key B-cell pathways deregulated differentially between Burkitt and other 
germinal center B-cell lymphomas.
Introduction
Differentiation of B-cells from uncommitted hematopoietic progenitors to antibody-
producing plasma cells is a key process in the adaptive immune response. This 
differentiation is regulated through the coordinated expression of transcription factors along 
with a wave of epigenetic modulation in the germinal center1–3, where genes encoding 
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immunoglobulins (IG) are somatically altered to optimize antibody affinity and avidity. The 
B-cell lymphomas most common in childhood, i.e. Burkitt lymphoma/leukemia, and in 
adulthood, i.e. diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, are 
supposed to derive from or resemble germinal center B-cells. They all show molecular 
features of germinal center -B-cells, with the mutational mechanisms active in the germinal 
center, such as somatic hypermutation, contributing to pathogenesis. Whereas DLBCL is 
heterogeneous with regard to genetic alterations and gene expression patterns of the tumor 
cells, Burkitt lymphoma and to a considerable extent also follicular lymphoma are much 
more homogenous lymphoma subtypes4,5. Burkitt lymphoma is almost invariably 
associated with an IG-MYC chromosomal translocation, i.e. juxtaposition of the MYC 
oncogene encoding a transcription factor next to one of the three immunoglobulin loci. The 
vast majority of follicular lymphoma, particularly those of grades 1 and 2, carry a t(14;18)
(q32;q21) chromosomal translocation juxtaposing the BCL2 oncogene next-to mostly the 
immunoglobulin heavy chain (IGH) locus6. Both lymphoma subtypes also display a 
different spectrum of secondary changes with e.g. mutations in cell cycle regulators and in 
the ID3/TCF3 transcription factor complex being highly prevalent in Burkitt lymphoma7–9. 
This deregulation of particular transcription factors in Burkitt lymphoma as well as recurrent 
mutations in chromatin modifiers such as CREBBP, MEF2B, EZH2 and KMT2D found in 
follicular lymphoma indicate that lymphoma pathogenesis also involves alterations in 
physiologic epigenetic modulation10–14. Clinically, patients affected with Burkitt 
lymphoma are significantly younger at diagnoses than those affected with follicular 
lymphoma. Moreover, Burkitt lymphoma shows a much higher proliferation rate and, thus, 
clinical aggressiveness than follicular lymphoma which is a more indolent disease. 
Intriguingly, despite these considerable differences, both, Burkitt lymphoma and follicular 
lymphoma, are supposed to derived from the very same cell compartment of the human 
body, the germinal center B-cell, as described above. Physiologically, normal germinal 
center B-cells oscillate between the centroblast state predominant in the dark zone of a 
germinal center and the centrocyte state predominant in the light zone of the germinal center. 
Burkitt lymphoma and follicular lymphoma cells have been proposed to be “frozen” in these 
functional states, i.e. Burkitt lymphoma resembling the dark-zone germinal center B-cell 
state and follicular lymphoma resembling the light-zone germinal center B-cell state15. This 
offers the unique opportunity to study to the epigenomic architecture of two neoplasms 
derived from the same cell of origin but showing considerably divergent genomic evolution.
Results
Burkitt and follicular lymphomas show genome-wide hypomethylation
To better understand the relationship between epigenomic architecture, genetic alterations 
and phenotype of the both germinal center B-cell lymphomas, we performed whole genome 
bisulfite (WGBS) and transcriptome sequencing of 13 IG-MYC-translocation positive 
Burkitt lymphoma and 9 BCL2-translocation positive follicular lymphoma (including 8 
follicular lymphoma grade 1 / 2 and one follicular lymphoma grade 3a/DLBCL) samples. As 
a reference, FACS-sorted germinal center B-cells from non-neoplastic tonsils of four donors 
were analyzed in parallel. The source of the sample material as well as the clinical follow-up 
of all patients are summarized in Supplementary Table 1. In total, 25 billion read pairs, with 
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at least 0.7 billion read pairs per sample, were obtained in the WGBS analysis. On average, 
92% of reads successfully mapped to the reference genome16, resulting in a mean coverage 
of 54x (Supplementary Table 2). Methylation rates called from the sequencing data showed 
excellent correlation with beta values obtained from Illumina HumanMethylation450K 
BeadChip analysis (Supplementary Table 3) from the same samples (mean R2=0.921; 
Supplementary Fig. 1). For transcriptome sequencing, an average of 150 million reads were 
obtained per case, of which 94.5% mapped to the human genome (Supplementary Table 4). 
Our analyses were complemented by 30x whole genome sequencing of tumors and matched 
controls from the same patients, and the germinal center B-cell populations, as well as 8 
additional Burkitt lymphoma (Supplementary Table 5).
Analysis of average genome wide CpG methylation revealed all lymphoma entities to be 
hypomethylated compared to non-neoplastic germinal center B-cells (Fig. 1a). However, 
considerable differences could be seen in the extent and variability of DNA methylation 
between the Burkitt lymphoma and follicular lymphoma groups, despite their common 
germinal center B-cell derivation (Fig. 1b). In addition to global hypomethylation, 
considerable DNA-methylation gains were observed in Burkitt lymphoma and follicular 
lymphoma samples at CpGs with low-level methylation in germinal center B-cells (GC-
B<0.3; Fig. 1c). To determine whether DNA methylation patterns vary between genome 
segments with different function, we compared methylation differences (average of Burkitt 
lymphoma and follicular lymphoma vs. germinal center B-cells) for 15 chromatin states 
(Supplementary Table 6) defined in the GM12878 lymphoblastoid cell line, representative of 
non-neoplastic mature B-cells17. For most chromatin states, individual segments showed 
either hyper- or hypomethylation largely neutralizing each other in this global analysis. 
However, changes in heterochromatin were mostly unidirectional, resulting in the greatest 
relative reduction of DNA methylation levels of any chromatin segment in the lymphoma 
samples. In stark contrast, poised promoters showed the strongest, but nevertheless small, 
increase in DNA methylation levels at a global level (Fig. 1d). In line with recent reports18, 
the observed small gains in poised promoter methylation were at times associated with 
increases in RNA expression of the associated genes in Burkitt lymphoma and follicular 
lymphoma samples (Fig. 1e; Supplementary Fig. 2).
DNA methylation downstream of promoters correlates with gene expression
Gene-centered analysis, including coding and non-coding genes, revealed increased levels of 
gene body methylation for highly expressed genes, which returned to background levels at 
transcription end sites (TES). High transcription levels typically were associated with the 
presence of large hypomethylated regions downstream of the transcription start sites (TSS), 
suggesting regulatory relevance for these regions (Fig. 2a; Supplementary Fig. 3). We 
applied an unbiased circular binary segmentation approach to our entire WGBS dataset, 
identifying 90,350 differentially methylated regions (DMRs) with 10 or more CpGs between 
Burkitt lymphoma, follicular lymphoma and germinal center B-cell controls. These DMRs 
included 36,775 and 27,607 DMRs between normal germinal center B-cells and follicular 
lymphoma and Burkitt lymphoma groups, respectively (Supplementary Table 7). The great 
majority of DMRs were located within transcribed (TSS to TES) rather than in promoter 
(1,500 nt upstream of TSS) or intergenic regions (Fig. 2b), with strong enrichment of DMRs 
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immediately downstream of TSS (Fig. 2c), analogous to the so-called “promoter 
downstream correlated regions” recently described in medulloblastoma19. No substantial 
size differences were observed between intra- and intergenic DMRs (Supplementary Fig. 4).
To define the role of these potential regulatory regions in Burkitt lymphoma and follicular 
lymphoma, we correlated methylation levels of intragenic DMRs (contained in the 
transcribed regions and up to 1,500 bp upstream of the TSS) with expression levels of the 
associated genes containing these DMRs. 40% of the intragenic DMRs showed significant 
(p<0.05) correlations between methylation and RNA expression (Fig. 2d), with the majority 
(64%) showing negative correlations (Fig. 2e; Supplementary Table 8). Overall, 85% of 
correlating DMRs (cDMRs) were located downstream of TSS. Negatively and positively 
cDMRs did not differ in size; however, the former were highly enriched downstream of TSS 
while the latter were more evenly distributed across the gene body (Supplementary Fig. 4). 
Examples of negatively cDMRs are shown in Supplementary Fig. 5. To ascertain the 
biological relevance of cDMR methylation, genes that previously had been reported as 
preferentially expressed in B cells of the dark zone (DZ) or light zone (LZ) of the germinal 
center15 were examined; around 22% of DZ- and 28% of LZ-specific genes possessed 
cDMRs. DZ-specific genes were predominantly hypomethylated and upregulated in Burkitt 
lymphoma, while hypermethylated and downregulated in follicular lymphoma samples 
(p<0.001; Fisher’s exact test, Figs. 2f,g); LZ-specific genes showed the opposite pattern 
(p<0.001; Fisher’s exact test, Figs. 2f,h). These data are in line with the view that the 
majority of Burkitt lymphoma are frozen in the DZ cell state while the majority of follicular 
lymphoma are frozen in the LZ cell state; moreover, they suggest that methylation at cDMRs 
could act to fix the otherwise physiologically transient functional states of DZ and LZ B-
cells in Burkitt lymphoma and follicular lymphoma samples, respectively. Examples include 
high expression of TCF3 and SMARCA4, higher expressed in DZ than in LZ B-cells and in 
Burkitt lymphoma than in follicular lymphoma, as well as NFkB2 and TNFAIP3, showing 
the opposite expression pattern. (Supplementary Fig. 6).
Differential methylation is common in key pathways in Burkitt lymphoma
The observed association between LZ- and DZ-specific gene expression prompted us to 
more fully evaluate cDMR involvement in differential gene expression between Burkitt 
lymphoma and follicular lymphoma. Ingenuity pathway analysis (IPA) was performed based 
on (i) all genes differentially expressed between Burkitt lymphoma and follicular lymphoma 
and (ii) the subset of differentially expressed genes with negatively correlating DMRs. 
Genes with positive correlations of methylation and expression, were used as negative 
control. The first gene set identified 60 pathways showing significant enrichment of 
differentially expressed genes; these were assigned scores indicating pathway activation 
(Supplementary Table 9). Analysis of genes with negatively correlating DMRs identified 58 
of the 60 pathways, all with comparable ratios of gene enrichment and activation scores. 
Pathway analysis based on positively correlating DMRs identified significantly fewer 
pathways (17/60; p<0.001; Fisher’s exact test). These data strongly indicate modulation of 
DNA methylation levels at negatively correlated cDMRs is a common mechanism in the 
regulation of differential gene expression in Burkitt lymphoma and follicular lymphoma. 
Next we sought to define the molecular mechanisms deregulated by DNA methylation, 
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particularly in Burkitt lymphoma using follicular lymphoma as a contrasting group. This 
was achieved by directly comparing Burkitt lymphoma with follicular lymphoma rather than 
with germinal center B-cells since the latter analysis would have been underpowered and 
potentially biased due to the smaller number of available germinal center B-cell samples 
(n=3). We identified 23 pathways with IPA that were differentially activated in Burkitt 
lymphoma and follicular lymphoma (Supplementary Table 10). To determine the directions 
of gene expression changes in those activated pathways relative to germinal center B 
controls, we visualized gene expression in Burkitt lymphoma, follicular lymphoma and 
germinal center B-cells for all 23 pathways (Supplementary Fig. 7). Gene ontology analysis 
of genes that were specifically downregulated in Burkitt lymphoma or follicular lymphoma 
in the 23 pathways identified suppression of processes related to inflammation and immunity 
in Burkitt lymphoma and cell cycle and DNA repair in follicular lymphoma (Supplementary 
Fig. 8). Remarkably, one of the few genes that, relative to germinal center B-cells, were 
upregulated in Burkitt lymphoma and downregulated in follicular lymphoma was IGF2BP1 
(Supplementary Fig. 9), an RNA-binding protein that stabilizes MYC20, underscoring its 
central importance in germinal center B-cell lymphoma biology.
Detailed pathway-based analyses showed that, e.g., DNA methylation was significantly 
associated with the downregulation of NFκB signaling and the upregulation of cell cycle 
control genes in Burkitt lymphoma (Supplementary Figs 10, 11), concurrent with the 
proliferation rates of close to 100%, typical for Burkitt lymphoma (Ki67 staining; 
Supplementary Table 1), and with previous reports on the molecular pathogenesis of Burkitt 
lymphoma7–9,21,22. The observed aberrant signaling was linked to differential methylation 
of key pathway genes in Burkitt lymphoma, including the hypermethylation and 
downregulation of JAK3 and STAT37 (Figs. 2h, i, j) in line with low JAK-STAT-pathway 
activity in Burkitt lymphoma. Another example of differential methylation of key regulatory 
genes in Burkitt lymphoma was hypomethylation and overexpression of the transcription 
factor TCF3 (Fig. 2k–m). Remarkably, the TCF3 gene even harbors two cDMRs of which 
cDMR1 contains a TCF3 binding site that is occupied in B-cells17, suggesting the 
possibility of a positive-feedback loop amplifying TCF3 transcription (Fig. 2k, l). Analysis 
of published TCF3-ChIP-Seq data of the Burkitt lymphoma cell lines BL-41 and 
NAMALWA9 confirmed TCF3 binding within cDMR1 that overlapped a common TCF3 
binding motif, and methylation levels of the CpGs surrounding this motif were inversely 
correlated with TCF3 expression in a larger set of 39 samples (Supplementary Fig. 12). 
These results indicate that, in addition to mutational mechanisms8,9,22, TCF3-cDMR 
hypomethylation contributes to TCF3 activation.
DNA mutation and methylation in sphingosine signaling
Pathway analysis also revealed deregulation of sphingosine-1-phosphate signaling in both 
Burkitt lymphoma and follicular lymphoma when compared to germinal center B-cells (Fig. 
3a). Sphingosine-1-phosphate receptor 2 (S1PR2) is frequently affected by loss-of-function 
mutations in Burkitt lymphoma and DLBCL, leading to increased AKT and migratory 
activity23. In our analysis we additionally identified cDMRs in several key pathway genes 
including PDGFRB, which is strongly upregulated in both Burkitt lymphoma and follicular 
lymphoma relative to germinal center B-cells (Fig. 3b), the stimulatory G-alpha-q protein 
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GNA11, upregulated in Burkitt lymphoma (Fig. 3c), and S1PR1 and the G-alpha-protein 
complex G(12/13)-member GNA12, which are overexpressed in follicular lymphoma (Figs. 
3d, e). Analysis of whole genome sequencing data detected mutually exclusive mutations in 
several G(12/13)-complex genes in 14 of 21 Burkitt lymphoma samples analyzed (Fig. 3f). 
These findings were corroborated by our previous description of RHOA mutations in 8.5% 
of Burkitt lymphoma samples in an extended cohort of 82 cases24 and by a recent study 
functionally implicating G(12/13) mutations in the development of germinal center B 
lymphomas23. Interestingly, 3 of the remaining 7 samples were affected by somatic 
mutations in two genes of the Gαi complex, GNAI1 and GNAI2, in 5 Burkitt lymphoma 
samples, including recurrent (n=3) GNAI2 R179H substitutions. The GαI complex can 
regulate several signaling pathways including AKT, ERK and protein kinase A (PKA). 
Inhibition of PKA in Burkitt lymphoma cell lines did not affect cell viability 
(Supplementary Fig. 13), suggesting that this pathway might not be essential in Burkitt 
lymphoma; however, mutations of the Gαs protein GNAS at the position homologous to 
GNAI2 R179H are known to cause upregulation of AKT signaling and cell migration in 
pancreatic adenocarcinoma and pituitary tumors25,26. Recently, it was proposed that, in 
addition to G(12/13) mutations, GNAI2 R179H mutations might increase proliferation and 
migration of DLBCL cells27. Our observations on sphingosine-phosphate and G-protein 
signaling suggest that mutation and DNA methylation of genes involved in these pathways 
might complement each other in suppressing G(12/13) and activating AKT signaling in 
Burkitt lymphoma.
Differential DNA methylation of transcription factor binding sites
Since cDMRs could be used to identify pathways contributing to the pathogenesis of Burkitt 
lymphoma through genomic mutation or deregulation by DNA methylation, we sought to 
identify sets of transcription factors (TFs) driving expression of genes with cDMRs. We 
intersected the cDMR dataset with TF binding sites (TFBS) data for 46 TF17,28. Significant 
enrichment of TFBS was observed for genes that were expressed at lower levels in Burkitt 
lymphoma than in follicular lymphoma samples, and were associated with hypermethylated 
(Burkitt lymphoma/follicular lymphoma) cDMRs in quadrant 2 (Q2) of the radar plot (Fig. 
4a). We selected the ten TFs displaying the highest correlation of TF and target gene 
expression (Supplementary Table 11) for subsequent analyses. Differential methylation of 
the corresponding TFBS typically was restricted to the TFBS itself and rapidly returned to 
background levels outside of it (Supplementary Fig. 14).
To understand how cDMR-methylation modulates TF-target gene expression, we plotted 
average methylation levels of cDMRs against average RNA expression of the associated 
genes for all 10 TFs (Fig. 4b). Target genes of STAT5A and BCL3, both enriched in Q2 (Fig. 
4a), displayed hypermethylation and reduced RNA expression in Burkitt lymphoma when 
compared to germinal center B-cell and follicular lymphoma samples, in agreement with the 
low level activity of the NFκB and JAK/STAT pathways previously reported in Burkitt 
lymphoma7. Similar patterns were observed for the target genes of other TFs in Q2. In Q4, 
we observed hypomethylation and activation of TCF3 target genes in Burkitt lymphoma 
when compared to follicular lymphoma samples. germinal center B-cell samples displayed 
intermediate methylation levels, more similar to follicular lymphoma methylation levels than 
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Burkitt lymphoma. As previously noted, mutations affecting TCF3, or its negative regulator 
ID3, detected by us and others8,22 in more than two-third of all sporadic Burkitt lymphoma 
have been proposed to foster TCF3-dependent gene expression driving Burkitt lymphoma-
cell proliferation9. Importantly, neither TF nor target gene expression were correlated with 
cell proliferation differences between Burkitt lymphoma and follicular lymphoma 
(Supplementary Fig. 15). Taken together, these findings suggest that both Burkitt 
lymphoma- and follicular lymphoma-specific gene expression programs are subject to 
regulation through DNA-methylation of TFBS.
To assess the impact of these TFs on target gene expression at a single gene level, we 
generated activity plots integrating and visualizing the correlation of target gene expression 
with cDMR methylation and the level of TF expression (Fig. 4c). Individual genes 
displaying the strongest activation in follicular lymphoma as compared to Burkitt lymphoma 
included the hallmark gene of follicular lymphomagenesis, BCL2, as well as CBX7, 
encoding a chromobox protein of the polycomb repressive complex 1, which was previously 
shown to be functionally involved in lymphomagenesis with high expression in follicular 
lymphoma29. Notably, strong activation in follicular lymphoma was also observed for a set 
of genes typically expressed in T-cells, including CD3E, CD2, GIMAP1 and ITK, in line 
with the differential role of bystander T-lymphocytes7 in follicular, in contrast to Burkitt, 
lymphomagenesis. TCF3 was among the genes strongly activated in Burkitt lymphoma, in 
line with the already above proposed auto-activation loop of its expression (Fig. 4c, d). 
Other strongly activated genes included the E2F family member E2F1, the POLD1 gene, 
which encodes the MYC-interacting polymerase D1, the TERT gene, which encodes 
telomerase as well as the SMARCA4 gene (Fig. 4c, e) encoding a member of the SWI/SNF 
nucleosome remodeling complex. Consistent with previous findings21, we could 
independently confirm overexpression of SMARCA4 RNA in Burkitt lymphoma using 
array-based analysis (Supplementary Fig. 16; Supplementary Table 12).
DNA mutation and methylation affect SMARCA4 in Burkitt lymphoma
Unexpectedly, the observed strong SMARCA4 transcriptional activation did not result in the 
upregulation of SMARCA4 target genes in Burkitt lymphoma, despite the fact that 
SMARCA4 binding sites were hypomethylated (Fig. 4a, f). These data suggest that 
suppression of SMARCA4-dependent expression does not occur through hypermethylation 
of its binding sites in the target genes, but rather is deregulated by DNA-methylation 
independent mechanisms in Burkitt lymphoma.
To elucidate the role of SMARCA4 in Burkitt lymphomagenesis, we performed an 
integrative data analysis (Fig. 5a) that showed high expression of SMARCA4 in Burkitt 
lymphoma associated with both decreased DNA methylation and chromatin reprogramming 
to active promoters (Chr19: 11.07-11.09 Mb) and enhancers to promoters (Chr19: 
11.15-11.16 Mb). Immunohistochemical staining found strong SMARCA4 protein (BRG1) 
expression in normal germinal center B-cells, but much less pronounced signal was seen in 
germinal center mantle and other B-cell compartments of the tonsils (Fig. 5b, 
Supplementary Table 13); in contrast, Burkitt lymphoma samples showed ubiquitous, high 
SMARCA4 protein expression in (Fig. 5c, Supplementary Table 13).
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Whole genome sequencing of the ICGC-MMML-Seq cohort identified SMARCA4 
mutations in 9 out of 21 Burkitt lymphoma samples. In line with previous reports30,31, 
these SMARCA4 mutations clustered in the helicase domain (Fig. 5d), revealing a mutation 
pattern that stands in strong contrast to the germline nonsense mutations predisposing to 
cancer syndromes32–35. Further investigation of the SMARCA4 mutational landscape from 
bona fide Burkitt lymphoma samples, including data from cell lines and published data, 
confirmed these observations (Supplementary Table 14). In the Burkitt lymphoma samples, 
mutant and wildtype SMARCA4 transcripts had similar expression levels (data not shown) 
and immunohistochemistry and immunofluorescence analyses of Burkitt lymphoma samples 
showed constant co-expression of SMARCA4 and MYC proteins in Burkitt lymphoma, 
regardless of the presence or absence of SMARCA4 mutations (Fig. 5c; Supplementary Fig. 
17; Supplementary Table 13).
Intriguingly, genomic mutations of other members of the SWI/SNF complex, including 
ARID1A, ARID1B and SMARCB1 were present in a subset of Burkitt lymphoma samples 
lacking SMARCA4 mutation (Fig. 5e; Supplementary Table 15), and, moreover, SWI/SNF 
complex genes showed increased expression levels in Burkitt lymphoma samples (Fig. 5f). 
Protein modeling36 (Fig. 5g) suggests that SMARCA4 mutations likely do not obstruct 
binding of the mutant protein to DNA, but some mutations might ablate helicase function 
directly, through interference with ATP-binding, or indirectly or by obstructing the 
interaction of the helicase N and C-terminal domains. It has recently been suggested, that 
such oncogenic SMARCA4 mutations like those observed herein in Burkitt lymphoma 
compromise TOP2A chromatin binding which is dependent on the ATPase activity of 
SMARCA4.
DNA methylation in lymphomas versus normal B-cell development
Finally, we aimed at comparing the DNA methylation patterns in Burkitt lymphoma and 
follicular lymphoma with the DNA methylome changes observed during human B-cell 
differentiation recently described by Kulis et al.37 Comparison of the DNA methylation 
levels determined by WGBS in the sorted germinal center B-cells in both studies showed an 
excellent agreement (correlation of means = 0.9799; see Supplementary Fig. 18a). Principal 
component analysis of the lymphomas analyzed herein together with the recently 
investigated normal B-cell populations showed the Burkitt lymphoma and follicular 
lymphoma to cluster together but distinctly from the normal B-cell subsets (Supplementary 
Fig. 18b). This clustering of the follicular lymphoma and Burkitt lymphoma separately from 
the physiologic germinal center B-cells relates most likely to the neoplastic process. To 
further investigate this, we analyzed the differences in DNA methylation between Burkitt 
lymphoma and follicular lymphoma, respectively, as compared to normal germinal center B-
cells for the 20 major modules of dynamic CpG methylation during B-cell development 
defined by Kulis et al. using both WGBS and array-based data (Supplementary Fig. 18c,d). 
In line with what has been described for diffuse large B-cell lymphoma by Kulis et al., we 
observe strongly increased DNA methylation of CpGs related to polycomb repressed regions 
(modules 17-20) and decreased DNA methylation of CpGs related to heterochromatin 
(modules 8 and 9) in both follicular lymphoma and Burkitt lymphoma as compared to 
germinal center B-cells. This extends the previous findings to the fact that also Burkitt 
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lymphoma and follicular lymphoma frequently acquire methylation changes in regions 
already undergoing dynamic methylation during normal B cell differentiation. Remarkably, 
when directly comparing the DNA methylation of Burkitt lymphoma and follicular 
lymphoma for the 20 modules, we hardly observed any differences. This suggests, that the 
DNA methylation differences between these two germinal center B-lymphoma subtypes 
indeed reflect the separate oncogenic paths driving these lymphomas rather than DNA 
methylation dynamics of normal B-cell differentiation. The only notable exception is 
module 11, which tends to lower DNA methylation in Burkitt lymphoma than in follicular 
lymphoma. Remarkably, the CpGs of this module, which are strongly enriched for enhancer 
sites, are selected by the fact that they switch their DNA methylation state from the naïve B-
cell to the germinal center B-cell stage. This as well as the enrichment for TCF3 binding 
sites in this module might to a certain extent relate to the above described freezing of the 
functional states of germinal center B-cells in Burkitt lymphoma and follicular lymphoma, 
respectively, as well as to the differential activation of oncogenic pathways in these 
lymphomas (Supplementary Fig. 18e).
Discussion
The presented DNA methylation analyses of Burkitt lymphoma and follicular lymphoma, 
both derived from germinal center B-cells, identified substantial differences in DNA 
methylation patterns. By combination with genome and transcriptome analyses these 
differences in DNA methylation can be linked to transcription factor activity and they are 
critical determinants of follicular lymphoma- and Burkitt lymphoma-specific gene 
expression patterns. In addition, lymphoma subtype-specific patterns of DNA methylation, 
integrated with mutation analysis, helped us identify complementary aberrant regulation of 
the, SWI/SNF and TCF3/ID3 and Gαi complexes as important contributors to Burkitt 
lymphomagenesis. Through our integrated analysis we now add a model for a potential 
dominant function of mutated SMARCA4 in Burkitt lymphomagenesis (Supplementary Fig. 
19). In this model, overexpression of TCF3, initiated by the combination of cDMR 
hypomethylation and mutation of TCF3 or its inhibitor ID3, leads to high expression of the 
inactive SMARCA4 protein which prevents methylation of its binding site and expression of 
its target genes due to its maintained binding competence in the absence of helicase activity.
Accession codes
WGBS data, mRNA-seq data, whole genome DNA-Seq
All sequencing data is available at the European Genome-phenome Archive (EGA, http://
www.ebi.ac.uk/ega/) under accession number EGAS00001001067 Please contact the data 
access committee (DAC; http://www.icgc.org/daco) of the International Cancer Genome 
Consortium (ICGC, http://www.icgc.org/) to get access to the data.
Chip Seq-Data
The raw sequencing read data is publically available from the European Nucleotide archive 
(ENA) (https://www.ebi.ac.uk/ena/). All ChIP cell line data is available under study 
ERP002586. The run identifiers are listed below:
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Tissue samples, basic characterization and sequencing of the ICGC MMML-Seq cohort
The ICGC MMML-Seq study has been approved by Ethics Committee of the Medical 
Faculty of the University of Kiel (A150/10) and of the recruiting centers. The ICGC 
MMML-Seq cohort consists of pre-treatment tumor tissue and corresponding germline 
material (peripheral blood, buffy coats shown to be tumor-free by clonality analyses) 
obtained with informed consent of the respective patients and / or in minors their legal 
guardian. In addition, sorted GC-B-cells from non-neoplastic tonsils were analyzed. In all 
tumor samples, basic characterization including histopathologic panel review, 
immunhistochemical and FISH analyses is being performed as described recently8. The 
tumor cell content in the cryo-preserved sample material was estimated to be at least 60% in 
all cases. Experimental procedures for DNA and RNA extraction, detection and sequencing 
of immunoglobulin rearrangements as well as whole genome and transcriptome sequencing 
of the ICGC MMML-Seq patient materials have been published previously8. All working 
steps were performed according to the manufacturer´s instructions or standard protocols 
unless otherwise stated. The sequences of PCR and sequencing primers are listed in 
Supplementary Table 16.
Validation sample cohort
A cohort of 103 previously characterized mature aggressive B-cell lymphomas from the 
Deutsche Krebshilfe Network “Molecular Mechanisms in Malignant Lymphomas” 
(MMML) in which previous studies had identified an IG-MYC fusion was used for 
validation purposes. These cases have been extensively characterized by histopathology 
review, immunohistochemistry, interphase FISH, gene expression profiling, array-CGH/
SNP-arrays and mutation analysis as described recently8. The protocols of the MMML 
network have been approved by central (University of Göttingen) and local review boards 
(Institutional Review Board of the Medical Faculty of the University of Kiel, D403/05).
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The cell lines DG-75, BL-2 and KARPAS-422 and Ca46 were obtained from the German 
Cell Culture Collection (DSMZ, Braunschweig, Germany). Cell lines were tested negative 
for mycoplasma contamination and their authenticity was confirmed by STR analysis using 
the StemElite ID System (Promega, Mannheim, Germany).
DNA methylation analysis
Whole-genome bisulfite sequencing—Strand-specific MethylC-seq libraries were 
prepared using the approach described by Lister et al.38 with the following modifications. 
Adaptor-ligated DNA fragments with 200–250 bp insert lengths were isolated and bisulfite 
conversion was performed using the EZ DNA Methylation Kit (Zymo Research). PCR 
amplification of the fragments was performed in six parallel reactions per sample using the 
FastStart High Fidelity PCR Kit (Roche). The thermocycling conditions were: 95 °C for 2 
min, 8 cycles of 95 °C for 30 s, 65 °C for 20 s and 72 °C for 45 s, ending with 72 °C for 7 
min. Library aliquots were pooled per sample and sequenced on a Illumina HiSeq2000 
platform, yielding 835 million (±81 million s.d.) 101 bp paired-end reads per sample on 
average.
HumanMethylation450k BeadChip—For bisulfite conversion of 0.5 to 1.0 μg genomic 
DNA the EZ DNA Methylation kit (ZymoResearch, Irvine, CA, USA) was applied 
according to the protocol supplied by the manufacturer. DNA methylation analysis using the 
Infinium HumanMethylation450k BeadChip (Illumina Inc., San Diego, CA, USA) was 
performed according the manufacturer’s instruction. The HumanMethylation450K 
BeadChip allows assaying more than 480,000 CpG sites in parallel39. DNA methylation 
data were processed using GenomeStudio software (v2011.1; methylation module 1.9.0; 
Illumina, Inc.) applying the default settings. The intrinsic controls present on the array were 
used for data normalization.
ChIP-seq library preparation protocols
ChIP-Seq data on H3K4me1, H3K4me3, H3K27ac, H3K9me3, H3K36me3, H3K27me3 
modification sensitive sites was performed on the BL-2, DG-75 and KARPAS-422 cell lines 
using the standard protocols generated within the Blueprint Consortium (http://
www.blueprint-epigenome.eu/index.cfm?p=7BF8A4B6-
F4FE-861A-2AD57A08D63D0B58).
Immunohistochemistry for c-MYC and SMARCA4
Conventional and fluorescence double-staining immunohistochemistry for c-MYC and 
SMARCA4 were done according to standard procedures using the rabbit monoclonal anti-c-
MYC antibody ab32072 (clone Y69, abcam plc., Cambridge, UK in 1:100 at pH 6.0) and the 
mouse monoclonal anti-Brg1 (SMARCA4) antibody sc-17796 (G-7) (Santa Cruz 
Biotechnology Inc., Heidelberg, Germany in 1:75 at pH 6.0). For conventional 
immunohistochemistry the secondary antibody Histofine® Simple Stain™ MAX PO (Multi) 
for simultaneous use with mouse and rabbit primary antibodies (medac GmbH, Wedel, 
Germany) was used. The secondary antibodies donkey anti-rabbit Alexa Fluor® 488 
Kretzmer et al. Page 11













(A21206) and donkey anti-mouse Alexa Fluor® 555 (A31570) (Life Technologies, 
Darmstadt, Germany) were used for fluorescence double staining. The photographs were 
taken using Axiophot (Zeiss, Oberkochen, Germany) and mounted ProgRes CF camera 
(Jenoptik, Jena, Germany) or mounted SPOT RT Slider digital CCD camera (Diagnostic 
Instruments Inc., USA).
PKA Inhibition
The BL cell line Ca46 was seeded at a density of 10.000 cells/well in duplicate. For PKA 
inhibition cells were treated with various concentration of the protein kinase A inhibitor 
PKI-6-22 (Santa Cruz Biotechnology, Texas, USA) ranging from 25nM to 500 nM. After 
72h of treatment the cell viability was measured using the Cell Titer Blue Assay (Promega, 
Mannheim, Germany).
Bioinformatics and statistical analysis
Whole genome sequencing data processing—Sequencing reads were mapped and 
aligned to the hg19 reference assembly plus decoy sequences (hs37d5) using Burrows-
Wheeler Aligner (BWA)40 (version 0.6.1) and somatic SNVs were identified as described in 
Jones et al.41. Indels were called by running Platypus42 on tumor and matched control. 
Empirical filters based on the filters built into Platypus, the read depth and variant read 
fraction in tumor and control, the base qualities and the genotype qualities were applied to 
extract high confidence somatic indels.
SNVs and Indels were annotated using Annovar according to Gencode gene annotation 
(v17) and overlapped with variants from dbSNP (build 135) and the 1000 Genome project 
database. SNV, indel and mutation calling are described in Jones et al.41 The mutational 
landscape of the samples is summarized in Supplementary Fig. 20.
Whole-genome methylation analysis—The mapping was done using segemehl43,44 
in its bisulfite methyl-C seq mode with default parameters and hg19 reference genome. 
Multiple lanes belonging to a single patient were mapped independently and merged 
together prior to methylation calling. The methylation calling was done using BAT (BAT - 
Bisulfite Analysis Toolkit, manuscript in preparation), which calculates the methylation rate, 
C/(C+T), for each cytosine.
We restricted our analysis to positions that showed a strand-informative coverage between 
15 and 150 reads in all samples of our study. This is the coverage calculated on reads that 
contain information for a C on its respective strand. Only reference CpG positions were 
taken into account, while reference non-CpG positions were analyzed separately. 
HumanMethylation450k BeadChips were used for verification. A linear model of the 
HumanMethylation450k BeadChip beta values and the WGBS methylation rates was 
performed using the stats package for R (3.1.0)45.
The assessment of the global, genome-wide methylation as well as chromatin state-specific 
methylation was performed using average (arithmetic mean) methylation levels.
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Next, we wanted to obtain a genome-wide segmentation of the methylation data we 
performed a top-down circular binary segmentation (CBS) similar to the method presented 
in Zhang et al in 201246 (Manuscript in preparation, http://www.bioinf.uni-leipzig.de/
Software/metilene/). In a pre-processing step to the CBS methylation gaps larger than 500 
nucleotides (e.g. centromeres) have been excluded. Assessment of differential methylation 
between pBL, pFL and GC B was done by computing pairwise differences of the group-wise 
average methylation. These differences were segmented using the modified CBS approach 
and tested for significance using sample methylation rates with a non-parametric test. As 
differentially methylated regions (DMRs) the top 10% and the bottom 10% segments were 
taken. Furthermore, a DMR was required to have a minimum of 10CpGs. In addition, our 
method did not impose further size constraints.
HumanMethylation450k BeadChip Methylation analysis—DNA methylation data 
were processed using GenomeStudio (v2011.1; methylation module 1.9.0; Illumina, Inc.) 
and Qlucore (Qlucore AB, Sweden) software, applying the default settings.
Whole-genome transcriptome analysis—Transcriptome data was mapped with 
segemehl43, 44 allowing for spliced alignments and using a minimum accuracy of 90%. 
Differential expression was analyzed using DESeq47 with default parameters and a 
significance criterion of 0.05 (p-value adjusted for multiple testing).
DMR correlation analysis—Correlating DMRs were identified based on prototypic BL 
(pBL; IG-MYC-translocation-positive; n=12) and prototypic FL (pFL; IG-BCL2-
translocation-positive and WHO grade 1 or 2; n=8) cases. To obtain DMRs correlating with 
the expression of nearby genes (DMR overlapping a gene or at most 1500nt upstream of its 
TSS), no linear relation was assumed and a spearman correlation test was performed. 
GENCODE48 V14 gene annotation was used for correlation analysis, including protein 
coding genes and other biotypes like antisense, lincRNA, miRNA and other noncoding 
genes (Supplementary Table 17). DMRs with a significant correlation test (p<0.05) were 
declared to be correlating DMRs (cDMRs).
Control of confounding factors—Control of confounding factors was performed for 
age bias (Supplementary Fig. 21), tumor cell content (Supplementary Fig. 22), proliferation 
rate as measured in Ki67 expression (Supplementary Fig. 22, Supplementary Fig. 15) and 
homogeneity of DMRs and cDMRs (Supplementary Fig. 23).
To test the hypothesis that transcription factor expression and transcription factor-target gene 
expression of TCF3, YY1, FOXM1, ZEB1, SMARCA4, STAT5A, PML, BATF and BCL3 is 
not associated with the proliferation status, we pooled all probesets of the TF genes 
(Supplementary Figure 15a) and their targets (Supplementary Figure 15b) and correlated 
them to the Ki-67 staining, a proliferation marker, in germinal center DLBCL (GCB 
DLBCL; n=160). In both cases (Spearman cor.=0.02 and Spearman cor.=0.043) no 
meaningful correlation was found. To analyze whether a subset of the TF genes or their 
targets are associated to the proliferation status we additionally carried out clustering 
analysis (Supplementary Fig. 15c–f). In both supervised and unsupervised clustering we 
found no such association.
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TFBS enrichment analysis—For all binding sites of each transcription factor annotated 
in GM1287849 we checked whether they are significantly enriched in one of the four classes 
of cDMRs. TFBS data was accessed under http://hgdownload.cse.ucsc.edu/goldenPath/hg19/
encodeDCC/wgEncodeHaibTfbs/48,50.
If available, replicates were merged. For significance testing bootstrapping was used. As a 
background model for this test we used the set of all pBL-pFL DMRs that were associated 
with a gene, i.e. including non-correlating DMRs.
Activity Plot—For each cDMR – gene pair an activation score y (y=rho*log2FC) was 
calculated. Rho is the spearman correlation coefficient of the cDMR – gene pair. These 
activation scores were assigned to TFs with a binding site in the cDMR. For TFs with more 
than one binding site in different cDMRs belonging to the same gene the average of the 
activation scores was used. The activation scores for the top 40 TF – gene pairs were plotted 
using the gplots package for R (3.1.0)45, 46.
Correlation tests, tests for equality of groups and boxplots—To increase 
robustness and to avoid the violation of assumptions (e.g. variance homogeneity, normal 
distribution) non-parametric tests were used throughout this study. For all correlations, we 
used Spearmans’s rank correlation method. The equality of the distributions of mean 
methylation values between the groups (Fig. 1b) was tested using a two-tailed non-
parametric Wilcoxon-Mann-Whitney-Test. The upper and lower “hinges” of all boxplots 
correspond to the 25th and 75th percentiles. The whisker extend from the hinge to the 
highest\lowest value that is within the 1.5-fold inter-quartile range (IQR) of the hinge. Data 
beyond the end of the whiskers are outliers and plotted as points
ChiP-segmentation for BL-2, DG-75, KARPAS-422 cell lines—Reads mapped to a 
gender matched reference (GRCh37) with BWA 0.5.9, with the read trimming parameter (-
q) set to 15. The alignments were sorted and duplicates marked with picard. Mappings with 
a MAPQ below 15 were filtered out with samtools (http://ftp.ebi.ac.uk/pub/databases/
blueprint/releases/current_release/homo_sapiens).
We segmented the DG-75, BL-2 and KARPAS-422 cell line genomes with the ChIP-seq data 
for the 6 histone modifications- described above. For this purpose, we used the 
implementation described by Ernst et al.51 in ChromHmm software (v1.03). The input data 
were the ChIP-Seq bed files with the genomic coordinates and strand orientation of mapped 
sequences (after remove duplicate reads). The genome was divided in consecutive 200 bp 
non-overlapping intervals and independently assigned present (1) or absent (0) for each of 
the 6 chromatin modifications. The assignment was based on the count of tags mapping to 
the interval and on the basis of a Poisson background model using a threshold of 10-4, as 
explained in Ernst et al. After binarization and for segmentation we used the eleven states 
model established by the Blueprint Consortium: (http://ftp.ebi.ac.uk/pub/databases/blueprint/
paper_data_sets/monocyte_neutrophil_2014/chromatin_states/full_histone_panel/
model_11_Blueprint_11.txt). Further, we computed the probability that each location is in a 
given chromatin state, and then assigned each 200-bp interval to its most likely state for each 
sample. Lastly, consecutive intervals within the same chromatin state were joined.
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SMARCA4 modeling—The structure of the helicase N-terminal helicase domain 
(DEXDc) and conserved C-terminal helicase domain of human SMARCA4 (residues 
Gln756 to Val1224) interacting with double-stranded DNA (dsDNA) was modelled on the 
structure of the Sulfolobus solfataricus SWI2/SNF2 ATPase core in complex with dsDNA52 
using Modeller53. This was superposed on the structure of Mycobacterium tuberculosis 
SecA54 bound to ADP, to position ADP in the final SMARCA4-dsDNA-ADP model shown 
in Fig. 5g.
Array based gene expression analysis—For the MMML cohort comprising 935 
samples including primary lymphomas, lymphoma cell lines and normal B-cell controls, 
array-based gene expression data from Affymetrix GeneChip U133A were available. Data of 
all gene expression arrays were jointly normalized with the VSN method55 as described 
previously21. Based on gene expression a “molecular BL (mBL) index”21 was calculated 
for each individual sample and was assigned one of the following molecular diagnoses; mBL 
(index ≥0.95), non-mBL (index score ≤0.05), or molecular intermediate (remaining 
cases)21. The lymphomas were also stratified according to their “pathway activation 
patterns”56. The cell of origin was classified according to the methods described by Wright 
et al42 using a modified classifier21.
To characterize the expression landscape of specific gene sets within lymphoma subgroups 
the samples were classified in two ways. First, cell lines (n=32) were compared with 
lymphomas classified as mBL (n=84)21 and follicular lymphoma (n=144). Diffuse large B-
cell lymphoma were subdivided into ABC (n=106), GCB (n=176) and unclassified 
(n=80)57. As normal controls tonsil samples (n=10), naïve B-cells (n=8), germinal center B-
cells (n=13) and post GC B-cells (n=9) were used.
In a second more stringent approach lymphomas with mBL signature21, BL-PAP “pathway 
activation pattern”56, IG-MYC translocation and without HIV infection were classified as 
pBL (n=58). Lymphomas with diagnosis of follicular lymphoma grade I or II, with t(14;18) 
translocation and without diffuse large B-cell lymphoma components were classified as pFL 
(n=75). Germinal center B-cell controls without EBV infection were termed GC-B (n=10).
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Figure 1. Loss of methylation in lymphoma.
(a) Circular plot for genome-wide group-average DNA methylation signals. A gradual loss 
of methylation in comparison to normal germinal center B-cells is observed (1: germinal 
center B-cells, n=4; 2: follicular lymphoma, n=9; 3: Burkitt lymphoma, n=13). (b) Boxplot 
of average methylation levels for lymphoma and normal controls. Methylation differences 
are significant (<0.05) for all pairwise comparisons except for follicular lymphoma vs. 
Burkitt lymphoma (p=0.13). Boxes indicate medians, 25th and 27th percentiles. Whiskers 
indicate the 1.5-fold inter-quartile ranges. GC-B, germinal center B-cells; BL, Burkitt 
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lymphoma; FL; follicular lymphoma. (c) Correlation of DNA methylation levels in Burkitt 
lymphoma, follicular lymphoma and germinal center B-cells at CpG resolution (blue=low 
density, orange=high density). (d) Average methylation difference (average of Burkitt 
lymphoma and follicular lymphoma vs. germinal center B-cells) in GM12878 chromatin 
segments. (e) Scatter plots of DNA methylation of poised promoters versus RNA expression 
of the associated genes.
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Figure 2. Differentially methylated regions (DMRs).
(a) Interdependence of DNA methylation and RNA expression levels across gene regions 
(mean of germinal center B-cells, follicular lymphoma and Burkitt lymphoma is shown). 
Genes were grouped by expression level (not: RPKM<0.1; low: 0.1<=RPKM<1; medium: 
1<=RPKM<10; high: 10<=RPKM) (b) Proportion of DMRs in promoters, transcribed- and 
intergenic regions. (c) Density plot of DMRs with respect to distance from the TSS (n = 22 
samples). (d) Proportion of DMRs in intragenic regions (1,500 nt upstreams of TSS to TES) 
that showed no, positive or negative correlations of DMR methylation and expression of the 
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associated gene. (e) Types and distribution of correlating DMRs (cDMRs). For about one-
third of DMRs (n=8,207; upper panel) degrees of methylation and RNA expression of 
associated genes correlated (p<0.05; Spearman). Of these cDMR-gene pairs, 67% showed 
negative correlation (Q2 and Q4). (f) Proportion of germinal center dark zone (DZ) and light 
zone (LZ) genes with negatively correlating DMR-gene pairs in Burkitt lymphoma and in 
follicular lymphoma. (g, h) Scatter and box plots of correlating DMRs of the DZ and LZ-
associated genes MDM1 and JAK3, respectively. (i) DNA methylation plot for STAT3, 
showing a cDMR in intron 6; red, methylated; blue, unmethylated (j) Correlations of cDMR 
methylation and expression for STAT3. (k) DNA methylation plot for TCF3, showing two 
cDMRs within the gene body. cDMR1 in intron 2 contains a TCF3 binding site. (l, m) 
Correlations of cDMR methylation and expression for TCF3. GC-B, germinal center B-
cells; BL, Burkitt lymphoma; FL; follicular lymphoma.
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Figure 3. Sphingosine-1-phosphate signaling is affected by complementary DNA mutation and 
methylation in germinal center B-lymphomas.
(a) Pathway of sphingosine-1-phosphate and related G-protein-coupled signaling. RNA 
expression of genes differentially expressed between lymphoma (Burkitt lymphoma and 
follicular lymphoma) and germinal center B-cells are indicated in red and green for up- and 
downregulation, respectively. Genes marked with blue outlines are associated with cDMRs. 
(b-e) Scatter and box plots of negatively correlating DMR methylation and RNA expression 
affecting genes involved in sphingosine-1-phosphate and G-protein signaling. (b) PDGFRB 
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(c) GNA11 (d) S1PR1 (e) GNA12 (f) Mutations identified in Burkitt lymphoma samples 
affecting the G12/13 (above dashed line) and Gαi (below dashed line) complexes. GC-B, 
germinal center B-cells; BL, Burkitt lymphoma; FL, follicular lymphoma.
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Figure 4. Enrichment of transcription factor binding sites (TFBS) in cDMRs.
(a) Radar plot showing the enrichment of binding sites of 46 transcription factors in cDMRs. 
Quadrants (Q1-Q4) classify cDMRs by correlation type (positive or negative) and direction 
of methylation and expression in Burkitt lymphoma vs. follicular lymphoma. Negatively and 
positively correlating DMR-gene pairs are located in Q2/Q4, and Q1/Q3, respectively. 
Concentric circles indicate levels of TFBS enrichment measured as percent binding sites of a 
particular TF found in cDMRs relative to all binding sites of this TF found in DMRs. Stars 
indicate TFBS that are significantly enriched (permutation test) in cDMRs. Red stars 
indicate the 10 TFs showing the best correlation of TF and average target gene expression. 
(b) Correlations of sample-wise average cDMR methylation and average target gene 
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expression for the 9 of the top 10 TFs showing negative correlations. (c) Activity map 
integrating the correlation of TFBS methylation and differential expression of target genes. 
Color and hue indicate the strength of inactivation (red) or activation (blue) in Burkitt 
lymphoma compared to follicular lymphoma samples. The top 40 target genes are shown for 
quadrants Q2 and Q4, each. (d,e) RNA expression of TCF3 (d) and SMARCA4 (e) in 
Burkitt lymphoma, follicular lymphoma and germinal center B-cells determined by 
microarray analysis in an extended lymphoma cohort. (f) Correlations of sample-wise 
average cDMR methylation and average target gene expression for SMARCA4. GC-B, 
germinal center B-cells; BL, Burkitt lymphoma; FL; follicular lymphoma.
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Figure 5. SMARCA4 genome architecture and protein expression.
(a) Genome browser view of the SMARCA4 locus. Chromatin segmentations of GM12878, 
BL2, DG-75 and KARPAS-422 cell lines (top), and average CpG methylation (middle) and 
RNA expression (bottom) of Burkitt lymphoma, follicular lymphoma and germinal center B-
cell samples. (b,c) Staining of SMARCA4 (BRG1) by immunohistochemistry in (b) a 
normal reactive follicle (tonsil), and (c) a Burkitt lymphoma with SMARCA4 R973W 
mutation (infiltrated lymph node; original magnification 400x; scale bar = 200 µm). (d) 
Accumulation of missense mutations in the SMARCA4 DEXDc helicase (cyan) and helicase 
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conserved C-terminal (grey) domains in Burkitt lymphoma samples. Heights of lollipops 
indicate relative numbers of mutations at that position. Red squares indicate severe changes 
in physico-chemical properties (score<0); yellow: 0<score<4. (e) Distribution of somatic 
mutations (SNVs or indels) of the SWI/SNF complex in Burkitt lymphomasuggests 
mutually exclusive mechanisms of inactivation. (f) Unsupervised analysis of SWI/SNF 
complex RNA-expression data (Affymetrix hgu133a) segregates Burkitt lymphoma and 
follicular lymphoma. (g) Model of SMARCA4 interaction with a DNA helix. Amino acid 
residues mutated in Burkitt lymphoma are indicated. but the model suggests them to ablate 
helicase function rather than DNA binding by interfering with ATP-binding, either directly 
or by obstructing the interaction of the helicase N and C-terminal domains. Cyan, DEXDc 
domain; grey, C-terminal helicase domain. ATP is shown with sticks colored by atom types. 
GC-B, germinal center B-cells; BL, Burkitt lymphoma; FL; follicular lymphoma.
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